The RSVpreF vaccine demonstrated 91% effectiveness against RSV-related lower respiratory tract disease in older adults during ...

The risk of respiratory syncytial virus, or RSV, is on the rise, along with that of other illnesses including the flu, ...

Respiratory illness activity is currently considered "high" in the United States, according to the CDC. In one state, it is ...

(HealthDay News) — Vaccines to protect against respiratory syncytial virus (RSV) in newborns and older adults are being more widely accepted by the American public, while confidence in other vaccines ...

The RSVPreF vaccine is safe and demonstrates immunobridging to efficacy among adults aged 18 to 59 who are at high risk for ...

As temperatures drop, the flu and respiratory syncytial virus (RSV) are making a comeback, according to Jacob Pierce, an infectious disease doctor at ECU Health ...

Newsweek has created a map showing states where respiratory syncytial virus (RSV) cases are surging.

NHS England said as of 29 December, there were 87 flu patients at the Royal Devon and Exeter Hospital along with 32 at the ...

The respiratory syncytial virus (RSV) vaccine may not protect older adults who are immunocompromised as much as their healthier peers, according to new research.

Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity do not respond as strongly ...

Respiratory viruses typically experience their highest levels in the wintertime, and this year will likely be no different.

The adjuvanted RSV prefusion F protein-based vaccine RSVPreF3-AS01E Arexvy was first FDA approved for older adults in May ...